OnabotulinumtoxinA as a Treatment for Hemiplegic Migraine
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 16-001072
Sponsor Protocol Number: 16-001072
About this study
Hemiplegic migraine is a rare subtype of migraine with aura, with symptoms affecting vision, speech and language, hearing, and sensory and motor disturbances. Muscle weakness and hemiplegia are defining characteristics of hemiplegic migraines. Compared to patients with typical migraine with aura, patients with hemiplegic migraine tend to have more prolonged aura symptoms. In some cases, reversible unilateral weakness may last days to weeks. The primary objective of this project is to evaluate the response of hemiplegic migraine patients evaluated at Mayo Clinic to onabotulinumtoxinA treatments.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- Patient evaluated at Mayo Clinic with available charts, records, and images for review.
- All patient ages will be included.
- Diagnosis of hemiplegic migraine.
- Treatment with onabotulinumtoxinA (150 units given every 3 months).
- Patient not meeting the aforementioned inclusion criteria.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Carrie Robertson, M.D.
Closed for enrollment
Publications are currently not available